A regenerative medicine company based in Haifa, Israel, says its placenta-based cell therapy product could be used to treat hundreds of patients who are suffering from respiratory and inflammatory complications associated with the COVID-19 coronavirus.
“We will first approach COVID-19 patients through compassionate use so we can treat them immediately,” explained Yaky Yanay, president and CEO of the company that produces the cell therapy. “We will be able to support the healthcare system and be able to help maintain and contain this disease.”
Full Story (The Jerusalem Post)
